Mereo BioPharma Group plc (MREO)

NASDAQ: MREO · Real-Time Price · USD
2.420
+0.030 (1.26%)
May 8, 2025, 4:00 PM - Market closed
1.26%
Market Cap 384.78M
Revenue (ttm) n/a
Net Income (ttm) -43.25M
Shares Out 159.00M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 907,929
Open 2.400
Previous Close 2.390
Day's Range 2.290 - 2.495
52-Week Range 1.575 - 5.020
Beta 0.47
Analysts Strong Buy
Price Target 7.71 (+218.6%)
Earnings Date May 19, 2025

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 36
Stock Exchange NASDAQ
Ticker Symbol MREO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is $7.71, which is an increase of 218.60% from the latest price.

Price Target
$7.71
(218.60% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025

6 weeks ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

2 months ago - GlobeNewsWire

Mereo BioPharma Provides Update on Lead Clinical Programs

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025

4 months ago - GlobeNewsWire

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that...

4 months ago - GlobeNewsWire

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from ...

5 months ago - Seeking Alpha

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that...

6 months ago - GlobeNewsWire

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo ...

6 months ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

8 months ago - GlobeNewsWire

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in ...

9 months ago - GlobeNewsWire

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the ...

11 months ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its f...

1 year ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively

1 year ago - GlobeNewsWire

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th...

Other symbols: KRROKRYSTAKWVE
1 year ago - Seeking Alpha

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

1 year ago - GlobeNewsWire

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an up...

1 year ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...

1 year ago - GlobeNewsWire

Mereo BioPharma to Present at the Jefferies Healthcare Conference

LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

2 years ago - GlobeNewsWire

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that ...

2 years ago - GlobeNewsWire

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

2 years ago - GlobeNewsWire

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

2 years ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...

2 years ago - GlobeNewsWire